We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Soleno Therapeutics Inc (SLNO) USD0.001

Sell:$50.00 Buy:$58.00 Change: $0.49 (0.96%)
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
Sell:$50.00
Buy:$58.00
Change: $0.49 (0.96%)
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
Sell:$50.00
Buy:$58.00
Change: $0.49 (0.96%)
Market closed |  Prices as at close on 4 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.

Contact details

Address:
100 Marine Parkway, Suite 400
REDWOOD CITY
94065
United States
Telephone:
+1 (650) 2138444
Website:
https://soleno.life/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SLNO
ISIN:
US8342033094
Market cap:
$2.21 billion
Shares in issue:
43.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Anish Bhatnagar
    President, Chief Executive Officer, Chief Operating Officer, Director
  • James Mackaness
    Chief Financial Officer
  • Michael Huang
    Senior Vice President - Clinical Development
  • Kristen Yen
    Senior Vice President - Clinical Operations
  • Patricia Hirano
    Vice President - Regulatory Affairs
  • Meredith Manning
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.